CA127-1030 (TRIDENT-3)

Thoracic tumors
Non-small cell lung cancer (NSCLC)
First-Line-Therapy (Metastatic Disease/Hematology)
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naive ROS1-positive non-small cell lung cancer (NSCLC).
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naive ROS1-positive non-small cell lung cancer (NSCLC).